Patents Examined by Chun Dahle
  • Patent number: 8937157
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: January 20, 2015
    Assignee: University of Washington
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Patent number: 8889130
    Abstract: The present invention relates to the treatment of osteoarthritis and pain using IL-1? and IL-1? binding proteins, including anti-IL-1? and anti-IL-1? antibodies and engineered multivalent and multispecific IL-1? and IL-1? binding proteins.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: November 18, 2014
    Assignee: Abbvie Inc.
    Inventor: Rajesh V. Kamath
  • Patent number: 8883147
    Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: November 11, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Bassil Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • Patent number: 8883973
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: November 11, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Patent number: 8871907
    Abstract: The present invention relates to a glycosylated immunoglobulin or a fragment thereof, in which an immunoglobulin variant, comprising one or more amino acid modifications selected from the group consisting of M160N, A195N, T243N, E265N, Y299T, F331T and Q346N, is additionally glycosylated, and a gene encoding the same.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: October 28, 2014
    Assignee: Korea Prime Pharm Co., Ltd
    Inventors: Yong-Hoon Chung, Ki-Wan Yi, Hoon-Sik Cho, Hong-Gyu Park, Kwang-Seong Kim
  • Patent number: 8858937
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: October 14, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Patent number: 8858950
    Abstract: A humanized murine antibody is provided that binds to the human insulin receptor (HIR). The humanized murine antibody is suitable for use as a Trojan horse to deliver pharmaceutical agents to human organs and tissue that express the HIR. The humanized murine antibody is especially well suited for delivering neuropharmaceutical agents from the blood stream to the brain across the blood brain barrier (BBB). The humanized murine antibody may be genetically fused to the pharmaceutical agent or it may be linked to the pharmaceutical agent using an avidin-biotin conjugation system.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: October 14, 2014
    Assignee: The Regents of the University of California
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 8852586
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: October 7, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Patent number: 8853363
    Abstract: The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either Fc?RIIb or Fc?RIIa.
    Type: Grant
    Filed: November 26, 2004
    Date of Patent: October 7, 2014
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Robert Huber, Peter Sondermann, Uwe Jacob, Kerstin Wendt, Chiara Cabrele, Luis Moroder
  • Patent number: 8853365
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: October 7, 2014
    Assignee: ABBVIE Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • Patent number: 8846874
    Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
    Type: Grant
    Filed: November 13, 2004
    Date of Patent: September 30, 2014
    Assignee: Hanmi Science Co., Ltd
    Inventors: Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 8841416
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: September 23, 2014
    Assignee: University of Washington
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Patent number: 8834871
    Abstract: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: September 16, 2014
    Assignee: The Board of the University of Texas System
    Inventor: E. Sally Ward Ober
  • Patent number: 8822645
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: September 2, 2014
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Jijie Gu, Peter C. Isakson
  • Patent number: 8822664
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: September 2, 2014
    Assignee: Affitech Research AS
    Inventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
  • Patent number: 8809503
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: August 19, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Patent number: 8802823
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: August 12, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Patent number: 8802820
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 12, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John Rudolph Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Patent number: 8785599
    Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than the antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The present invention also provides the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: July 22, 2014
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Robyn Gerena
  • Patent number: 8778339
    Abstract: The present invention relates to methods of treatment, prevention, management or amelioration of one or more symptoms of diseases or disorders associated with CD20 expression that encompass administration of a combination of: (A) one or more antibodies that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies bind Fc?RIIA, and (B) one or more antibodies that specifically bind to CD20. Such methods include methods of treating, preventing, managing or ameliorating one or more symptoms of a B cell related disease or disorder or an inflammatory disorder. The invention also provides pharmaceutical compositions comprising an anti-Fc?RIIB antibody and an anti-CD20 antibody.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: July 15, 2014
    Assignee: MacroGenics, Inc.
    Inventors: Nadine Tuaillon, Christopher Rankin